CHGB · Partner-reported service scope
Stem Cells & Cellular Derivatives
Stem cell portfolio and cellular derivative production, including stem cell and immune cell exosomes for cell-free therapeutic and diagnostic applications.
- Partner-reported scope
- Method
CHGB · Partner-reported
Service capabilities
The following scope is reported by the partner. Quantities describe the partner portfolio and do not represent VectorGene’s own track record.
- hUC-MSCs
- Human umbilical cord mesenchymal stem cells.
- Amniotic stem cells
- Vascular endothelial cells
- Neural stem cells
- Adipose-derived stem cells
- Fibroblasts
- Stem cell exosomes
- Immune cell exosomes
Explore services in this category.
Read each service’s complete scope and regulatory note. These links help you explore the portfolio; programme-specific suitability requires feasibility assessment.
Review each cellular product and derivative separately.
Stem-cell preparations and cellular derivatives vary in source, processing and intended use. Start with a precise product description and the evidence supporting the proposed activity. The institution’s review can then address materials, methods, ethics and the applicable product-specific pathway.
FDA regulates cellular and gene therapy products and maintains a list of specific approved products. A technology category or manufacturing capability should therefore be assessed separately from the status of a particular product.
FDA: Cellular & Gene Therapy ProductsExternal references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.
Questions for the programme brief
Which material and activity?
Identify the source, processing, characterisation and whether the intended activity is research or clinical development.
Which evidence and permissions?
Request product-specific supporting records, consent arrangements and the authority or ethics pathway to be confirmed.
Which quality boundary?
Agree identity, purity, consistency, storage and traceability requirements for the material actually being considered.
What to prepare for review
- Product and intended-use description
- Source, consent and characterisation records
- Product-specific evidence and permissions
Working environments
Cell culture and analysis environments.
Illustrative stock photography provides context for the people, processes and working environments behind this capability.
Explore three cutaway laboratory rooms with workbenches and air-handling panels. This is an illustrative object, not a facility specification.
- Material
- Identify the source, processing, characterisation and whether the intended activity is research or clinical development.
- Evidence
- Request product-specific supporting records, consent arrangements and the authority or ethics pathway to be confirmed.
- Quality
- Agree identity, purity, consistency, storage and traceability requirements for the material actually being considered.
